Novo Nordisk
-
healthOpenAI and Novo Nordisk Forge AI Partnership to Revolutionize Drug Discovery
OpenAI's advanced AI models will accelerate Novo Nordisk's drug discovery, development, and delivery processes, aiming to bring life-changing therapies to patients faster.
-
healthNovo Nordisk Unveils Higher-Dose Semaglutide for Weight Loss
Novo Nordisk introduces a new 7.2 mg semaglutide injection, offering adults an enhanced therapeutic option for weight management and potential for greater loss.
-
healthFDA Approves Eli Lilly’s Oral GLP-1 Weight-Loss Pill Foundayo
The FDA has fast-tracked approval of Foundayo, Eli Lilly’s once-daily oral GLP-1 pill for obesity and overweight adults with comorbidities, following rapid clinical results and safety warnings.
-
healthExperts Divided on Microdosing Ozempic for Longevity
Top medical professionals clash over the safety and efficacy of microdosing GLP-1 drugs like Ozempic for metabolic health and longevity beyond approved indications.
-
healthIndia's Generic Semaglutide Surge Could Reshape Global Obesity Treatment
With Novo Nordisk's semaglutide patent expiring in India, domestic manufacturers are preparing dozens of affordable generics, potentially slashing costs and expanding access to GLP-1 weight-loss drugs worldwide.
-
healthFDA Cites Novo Nordisk for Failing to Report Patient Deaths Linked to GLP-1 Drugs
The FDA issued a warning letter accusing Novo Nordisk of systemic failures in reporting serious side effects-including deaths-of patients using Ozempic and Wegovy.
-
healthFDA Cracks Down on 30 Telehealth Firms Over Illegal GLP-1 Marketing
The FDA has issued warning letters to 30 telehealth companies for misleading marketing of GLP-1 products, including false claims and obscured sourcing.
-
healthAnti-Obesity Drug Set for Drastic Price Drop Post-Patent
New study reveals blockbuster anti-obesity and diabetes drug, semaglutide, could cost as little as $3 per month to manufacture, offering hope for wider access.